Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Targeted bone marrow radiation tested for myeloma relapse – trial halted early

NCT ID NCT01794572

Disease control Sponsor: Institut Cancerologie de l'Ouest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a combination of high-dose chemotherapy (melphalan) and escalating doses of total bone marrow irradiation, followed by a stem cell rescue, in 13 people with multiple myeloma that had returned after initial treatment. The goal was to find the highest safe radiation dose. The trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Total bone marrow irradiation and melphalan chemotherapy
What this could lead to
If successful, this approach could offer a more targeted way to deliver high-dose therapy before a stem cell transplant for relapsed multiple myeloma.
What could go wrong
This was a very early, small trial that was terminated before completion. The combination of high-dose radiation and chemotherapy carries significant risks, including severe side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

13 people

The number who actually took part.

Started

Apr 2013

Finished

Oct 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Multiple Myeloma in first relapse. * In Complete or very good partial remission * Available Collected Autologous Peripheral Stem cells: 2.5x106 CD34+/Kg Exclusion Criteria: * Uncontrolled visceral disease: kidney, heart, lung, diabetes mellitus * Previous Total body irradiation * Any previous radiation dose to the spinal cord which could reach to 45gy equivalent, including the proposed TBMI * Amyloidosis * Brain localizations

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma in relapse are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pathologic Complete Response plasma cell myeloma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma in relapse

Contacts and locations

Locations

  • CHU Claude Huriez, service d'hématologie

    Lille, 59037, France

  • CHU Haut-Leveque, service d'Hématologie

    Bordeaux, 33604, France

  • CHU Hautepierre, service d'hématologie

    Strasbourg, 67098, France

  • CHU Hotel-Dieu, service d'hématologie

    Nantes, 44093, France

  • CLCC Bergonie, service de radiotherapie

    Bordeaux, 33076, France

  • CLCC ICO, service de radiothérapie

    Saint-Herblain, 44805, France

  • CLCC Oscar Lambret, service de radiothérapie

    Lille, 59020, France

  • CLCC Paul Strauss, service de radiothérapie

    Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.